Press Releases

All Releases
View Summary Pharmacyclics Reports First Quarter 2013 Results
May 1, 2013
PDF 41.0 KB Add to Briefcase
View Summary Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
Apr 24, 2013
PDF 8.4 KB Add to Briefcase
View Summary Pharmacyclics Completes Enrollment of First Phase III Ibrutinib CLL Study - RESONATE™ and Announces Completion of Enrollment of Phase II Ibrutinib MCL Study - SPARK
Apr 18, 2013
PDF 13.8 KB Add to Briefcase
View Summary Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Apr 11, 2013
PDF 13.2 KB Add to Briefcase
View Summary Phase II Ibrutinib Monotherapy Study Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
Apr 8, 2013
PDF 13.3 KB Add to Briefcase
View Summary Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
Apr 8, 2013
PDF 12.8 KB Add to Briefcase
View Summary Pharmacyclics, Inc. Prices Public Offering of Common Stock
Mar 8, 2013
PDF 8.3 KB Add to Briefcase
View Summary Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
Mar 7, 2013
PDF 9.1 KB Add to Briefcase
View Summary Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
Feb 14, 2013
PDF 33.1 KB Add to Briefcase
View Summary Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
Feb 12, 2013
PDF 15.5 KB Add to Briefcase
View Summary Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
Feb 7, 2013
PDF 8.5 KB Add to Briefcase
View Summary Pharmacyclics® Announces Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) at American Society of Hematology (ASH) Annual Meeting
Dec 11, 2012
PDF 23.0 KB Add to Briefcase
View Summary Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, Suggest High and Durable Responses in Relapsed/Refractory Mantle Cell Lymphoma
Dec 11, 2012
PDF 15.0 KB Add to Briefcase
View Summary Data Presented at American Society of Hematology from Ibrutinib Phase 1b/2 and Phase 2 Trials Suggest High and Durable Response in Chronic Lymphocytic Leukemia
Dec 8, 2012
PDF 17.4 KB Add to Briefcase
View Summary Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
Nov 5, 2012
PDF 33.3 KB Add to Briefcase
View Summary Pharmacyclics® Triggers Another Significant Milestone Payment for Phase III Chronic Lymphocytic Leukemia Combination Trial
Oct 15, 2012
PDF 12.8 KB Add to Briefcase
View Summary Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
Sep 5, 2012
PDF 37.0 KB Add to Briefcase
View Summary Pharmacyclics® Triggers Significant Milestone Payment For Mantle Cell Lymphoma Clinical Trial
Aug 20, 2012
PDF 11.7 KB Add to Briefcase
View Summary Pharmacyclics® Appoints Joshua T. Brumm Executive Vice President of Finance
Aug 14, 2012
PDF 8.7 KB Add to Briefcase
View Summary /C O R R E C T I O N -- Pharmacyclics, Inc./
Aug 1, 2012
PDF 15.4 KB Add to Briefcase
Showing 1-20 of 310 Page: 1 2 3 4 5 ... 16  Next 20
Add to Briefcase = add release to Briefcase